Want to join the conversation?
$REGN and Sanofi said that the Ministry of Health, Labor & Welfare in Japan has granted marketing & manufacturing authorization for Praluent for the treatment of uncontrolled low-density lipoprotein cholesterol in certain adult patients with hypercholesterolemia at high cardiovascular risk. Praluent is also approved in the US, EU, Canada & Mexico.
Looking forward for $STT’s 2017 first quarter earnings results. Is it possible for them to outperform their estimates?
$HAL has cautioned that its 1Q profit is likely to miss projections. I’m expecting EPS to be in low single digits.!
$GOOG is losing more advertisers after the boycotts over extremist ads. Future is not so bright for Google in the advertising sector..!